Euroscreen FAST: A fully Dedicated Business Unit for GPCR Screening Will Present its Expanded Services at SBS Meeting

Michel Detheux, Ph.D., Director Euroscreen FAST Business Unit ,will present Euroscreen FAST capabilities and expertise at the 14th Annual Conference and Exhibition of the Society for Biomolecular Sciences (SBS Meeting) in St. Louis.

Brussels, Belgium (PRWEB) April 1, 2008 -- Euroscreen SA dedicates an independent Business Unit for its services and screening activities related to G protein coupled receptors (GPCRs). This business unit, called Euroscreen FAST) integrates the specific resources and strategy to offer its worldwide-recognized expertise to customers in academic, biotech and pharmaceutical research groups. Services encompass functional High Throughput Screening, molecular pharmacology, functional profiling, functional antibodies development and testing, orphan receptor screening and custom assay development -- all based upon the largest catalog of functional assays targeting GPCRs. The high quality of Euroscreen FAST data, our reactivity and flexibility to the customers timelines have been appreciated during 14 years of validation and improvements in GPCR assay development by Euroscreen.

Michel Detheux, Ph.D., Director Euroscreen FAST Business Unit ,will present Euroscreen FAST capabilities and expertise at the 14th Annual Conference and Exhibition of the Society for Biomolecular Sciences (SBS Meeting) in St. Louis.

About EUROSCREEN S.A.
EUROSCREEN is a privately held preclinical-stage biopharmaceutical company based in Brussels Belgium, focused on the discovery and development of small molecule drugs for unmet medical needs. Founded in 1994, as a spin-off of the "Université Libre de Bruxelles", initially developing and commercializing G Protein-Coupled Receptors (GPCR) reagents, EUROSCREEN is now developing a pipeline of preclinical candidates targeting proprietary GPCR, such as CCR5, as well as several preclinical-stage collaborations with partners, using its worldwide recognized expertise on this critical class of drug targets. EUROSCREEN pursues a dual business model strategy of combining its internal programs on high value targets (Euroscreen DRUG DISCOVERY) with its fully dedicated Business Unit (Euroscreen FAST) providing GPCR customized screening and other services for biotech and pharmaceutical companies around the world. EUROSCREEN has developed a broad target portfolio for licensing intellectual property rights to pharmaceutical companies for the development of therapeutic drugs that act through these targets, including CCR5, Chemerin receptor, GPR43, GPR7/8, ORL1-R, FPRL2, purinergic receptors (P2Y4, P2Y11 and P2Y13) and SHIP2. EUROSCREEN has discovery and licensing partnerships with Alchemia, AstraZeneca, Boehringer-Ingelheim, Cephalon, GNF, Grunenthal, HGS, ICOS owned by Lilly, Medarex, Novartis and Pfizer.

###